Table 2.
Plasma tenofovir, tenofovir alafenamide, emtricitabine and intracellular tenofovir diphosphate and emtricitabine triphosphate GMRs of the main PK parameters following administration of 25/200 mg of tenofovir alafenamide/emtricitabine once daily with and without rifampicin and 300 mg of tenofovir disoproxil fumarate administered alone
| PK parameter | TFV GMR (90% CI) |
||
|---|---|---|---|
| TAF/FTC+RIF versus TAF/FTC | TDF versus TAF/FTC | TAF/FTC+RIF versus TDF | |
| C max | 0.35 (0.30–0.42) | 13.57 (11.98–15.36) | 0.03 (0.02–0.03) |
| C 24 | 0.45 (0.42–0.50) | 7.15 (6.56–7.79) | 0.06 (0.06–0.07) |
| AUC0–24 | 0.46 (0.40–0.52) | 11.10 (9.96–12.36) | 0.04 (0.04–0.04) |
|
| |||
| TAF GMR (90% CI) | FTC GMR (90% CI) | ||
| TAF/FTC/RIF versus TAF/FTC | TAF/FTC/RIF versus TAF/FTC | ||
|
| |||
| C max | 0.50 (0.42–0.61) | 1.01 (0.90–1.14) | |
| C 24 | – | 0.70 (0.61–0.79) | |
| AUC0–24 | 0.45 (0.33–0.60) | 0.99 (0.90–1.08) | |
|
| |||
| TFV-DP GMR (90% CI) | |||
|
| |||
| TAF/FTC+RIF versus TAF/FTC | TAF/FTC versus TDF | TAF/FTC+RIF versus TDF | |
|
| |||
| C max | 0.62 (0.52–0.74) | 7.14 (5.0–10) | 4.40 (3.09–6.27) |
| C 24 | 0.57 (0.47–0.71) | 7.14 (5.26–10) | 4.15 (2.89–5.94) |
| AUC0–24 | 0.64 (0.54–0.75) | 6.67 (4.35–10) | 4.21 (2.98–5.95) |
|
| |||
| FTC-TP GMR (90% CI) | |||
| TAF/FTC/RIF versus TAF/FTC | |||
|
| |||
| C max | 0.99 (0.85–1.15) | ||
| C 24 | 0.87 (0.71–1.07) | ||
| AUC0–24 | 1.03 (0.86–1.24) | ||
TFV, tenofovir; TAF, tenofovir alafenamide; FTC, emtricitabine; TFV-DP, tenofovir diphosphate; FTC-TP, emtricitabine triphosphate; RIF, rifampicin; TDF, tenofovir disoproxil fumarate.